Akira Yoshida (@akiyosshii1)

Pinned

A

Akira Yoshida@akiyosshii1 · Jul 15

thrilled to share our latest work from @NMSrheumatology🇯🇵, highlighting a distinct cytokine profile of anti-MDA5-positive DM, with elevations of IFN-β and λ3. The combination of serum IFN-α, β, and λ3 levels could serve as a prognostic biomarker. #MDA5 doi.org/10.1038/s41598…

akiyosshii1's tweet card. Scientific Reports - Dysregulated type I/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis

1

5

14

2

2.0K

Akira Yoshida Retweeted

R

Rohit Aggarwal@docrota · Jul 24

After success in RA, PsA, it's time to define & achieve remission/ low disease activity in Myositis. Here is our review on remission/low disease criteria and significant unmet need in myositis. Welcome feedback to develop & validate IIM remission ! sciencedirect.com/science/articl…

0

11

33

8

1.0K

A

Akira Yoshida@akiyosshii1 · Jul 19

📢吉田晃先生の抗MDA5抗体陽性皮膚筋炎に関する研究論文が出ました。他の皮膚筋炎、SLE、COVIDを対照とし、血中のバイオマーカーを比較解析。 ✅IFN-λ3はMDA5群で著増 ✅IL-6はCOVID群で著増 ✅IFN-α/βはMDA5群で増加 ✅IFN-α/βとIFN-λ3の上昇の有無の組み合わせでMDA5群は3つのクラスターに分類可能

AAkira Yoshida@akiyosshii1 · Jul 15

thrilled to share our latest work from @NMSrheumatology🇯🇵, highlighting a distinct cytokine profile of anti-MDA5-positive DM, with elevations of IFN-β and λ3. The combination of serum IFN-α, β, and λ3 levels could serve as a prognostic biomarker. #MDA5 doi.org/10.1038/s41598…

0

2

20

3

1.0K

Akira Yoshida Retweeted

A

American College of Rheumatology@ACRheum · Jul 4

Why is lung involvement so feared in #myositis? What’s the story behind “hiker’s feet?” Our latest episode dives into the data behind the CLASS project on anti-synthetase syndrome. LISTEN & LEARN → acr.tw/4egbOsI @ACR_Journals

0

4

6

0

966

Akira Yoshida Retweeted

A

American College of Rheumatology@ACRheum · Jun 30

Just how critical was the presence of interstitial lung disease among the CLASS study cohort? Dr. Faghihi Kashani explains why it became important HERE → acr.tw/4egbOsI

0

3

9

1

1.0K

A

Akira Yoshida@akiyosshii1 · Jun 27

Thanks to @jrheum for accepting the article and inviting for the interview! Truly honored our article to be picked as Editor’s Spotlight ! Special Thanks to Anushka from India and Maha from Saudi - the emerging leaders in myositis.

TThe Journal of Rheumatology@jrheum · Jun 25

Editor's Picks Spotlight Role of CD19 Chimeric Antigen Receptor T Cell Therapy in Idiopathic Inflammatory Myopathies 🖊️ Drs. Anushka Aggarwal, Maha Almackenzie and Rohit Aggarwal @Anushka2k7 @docrota 📖 jrheum.org/cgi/content/fu… 📽️ youtu.be/H2L91C4x_A0

1

3

38

1

2.0K

Akira Yoshida Retweeted

T

The Journal of Rheumatology@jrheum · Jun 25

Editor's Picks Spotlight Role of CD19 Chimeric Antigen Receptor T Cell Therapy in Idiopathic Inflammatory Myopathies 🖊️ Drs. Anushka Aggarwal, Maha Almackenzie and Rohit Aggarwal @Anushka2k7 @docrota 📖 jrheum.org/cgi/content/fu… 📽️ youtu.be/H2L91C4x_A0

0

2

4

0

4.0K

A

Akira Yoshida@akiyosshii1 · Jun 24

Thank you so much for having us and the wonderful opportunity to present the data from our international collaborative effort. I am proud to be a member of the CLASS family!

AAmerican College of Rheumatology@ACRheum · Jun 24

NEW EPISODE! The CLASS project brings together global investigators to better define anti-synthetase syndrome. Hear from the authors about clinical domains, antibody testing, & what’s next in autoimmune disease research. LISTEN NOW → acr.tw/4egbOsI @ACR_Journals

0

3

9

0

2.0K

Akira Yoshida Retweeted

A

Autoinmunes Medicina Interna Parc Taulí@autoinMI_tauli · Jun 14

New EULAR/ACR classification criteria for Antisynthetase Syndrome ✅ Anti-ARS antibodies & ILD are top drivers 🧪 ANA, SSA, MSA testing crucial to apply/exclude criteria 🧠 Score ≥5.5 + anti-ARS = definite ASyS ⏩ most weighted items = anti-ARS , ILD, myositis #EULAR2025

1

59

121

54

5.0K

Akira Yoshida Retweeted

昭

昭和医科大学病院リウマチ膠原病内科 Div Rheumatol, Showa Med U🇯🇵@rheum_showa · Jun 14

【EULAR2025報告】 EULAR-ACR、ARS抗体症候群の分類基準の発表 ✅ILDは最高得点の臨床変数（NSIP/OP）であり、ASySの特徴 ✅臨床領域：ILD、筋炎、関節炎 ✅血清学的ドメイン：抗ARS、抗Ro52/抗SSA、および細胞質ANAパターン #EULAR2025

0

4

34

17

5.0K

Akira Yoshida Retweeted

M

Matteo Piga@RMD_clinic · Jun 14

🚨 NEW classification criteria for #ASyS #antisynthetasesyndrome presented by @docrota and @Lollo7770 ➡️ clinical domain ➡️ other clinical features ➡️ serologic domain Great achievement! 👏🏼👏🏼👏🏼 #EULAR2025 @eular_org @ACR_Journals @eular_ARD

2

32

104

28

5.0K

Akira Yoshida Retweeted

A

Anushka Aggarwal@Anushka2k7 · Jun 3

Editor's Choice: Find our recent interview discussing the role of CAR T-cell therapy in myositis with Dr Earl Silverman from Journal of Rheumatology! 😀📞📽💡 Do check out the full article in Editor's pick spotlight! @docrota @jrheum jrheum.org/content/viewin…

1

5

19

1

3.0K

Akira Yoshida Retweeted

R

Rheuma Doc@LastManStand85 · Jun 4

Nice review article published this month in The Rheumatology Oxford Journal Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review👇#myositis #Rheumatology #MedTwitter Full Ref included below

3

44

126

103

7.0K

Akira Yoshida Retweeted

R

Rohit Aggarwal@docrota · May 23

Dear Friends — Looking for a senior PhD-level Biostatistician (Europe/USA) for a global, prestigious, high-impact international project on Myositis. Funding is provided. Interested or know someone? 📩 [email protected]

1

10

20

2

2.0K

Akira Yoshida Retweeted

A

ACR_Journals@ACR_Journals · May 22

Retrospective obs. study explored dynamics of autoantibodies over time in SLE. Results showed that anti-Sm/RNP and anti-dsDNA, in contrast to anti-SSA/SSB, frequently fluctuated and their levels can decrease following B cell-targeted treatment A&R doi.org/10.1002/art.43…

0

13

25

8

3.0K

Akira Yoshida Retweeted

L

Lorenzo Cavagna@Lollo7770 · May 4

And We Will use it in the incoming Classification Criteria of antisynthetase syndrome: ASyS Important that from Now all will use this as official abbreviation

0

2

6

0

441

A

Akira Yoshida@akiyosshii1 · May 4

Update on Consensus nomenclature and abbreviation for anti-synthetase syndrome. Furst major step towards homogeneity in literature. 📚📚✅️

RRohit Aggarwal@docrota · May 3

Anti-synthetase syndrome (ASyS): Consensus on nomenclature and abbreviation for anti-synthetase syndrome is now done. Everyone should use this nomenclature and abbreviation for the ASyS going forward: an IMACS project academic.oup.com/rheumatology/a…

0

1

6

0

313

Akira Yoshida Retweeted

R

Rohit Aggarwal@docrota · May 3

Anti-synthetase syndrome (ASyS): Consensus on nomenclature and abbreviation for anti-synthetase syndrome is now done. Everyone should use this nomenclature and abbreviation for the ASyS going forward: an IMACS project academic.oup.com/rheumatology/a…

9

49

122

33

7.0K

Akira Yoshida Retweeted

日

日本医科大学リウマチ膠原病内科 Nippon Medical School Rheumatology@NMSrheumatology · Apr 10

＃膠原病に伴う＃間質性肺疾患診断・治療指針2025 が本日発刊です。初版の2020年版が発刊されてから5年間でこの領域は飛躍的な進歩を遂げています。今回も＃日本リウマチ学会から桑名正隆教授、＃日本呼吸器学会から近藤康博教授を始めとするエキスパートの先生方の委員会による編纂です。

0

15

105

21

16.0K

Akira Yoshida Retweeted

A

ACR_Journals@ACR_Journals · Mar 31

April Arthritis & Rheumatology Clinical Connections •Neutrophil Activation Markers and RA Treatment Response to JAK1/2 Inhibitors •Clinical Characteristics of Anti-Synthetase Syndrome: Analysis from the CLASS Project acr.tw/426RTql

0

6

13

2

2.0K